Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of SHR0532 in Mild Hypertension
NCT03971929Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR0532 in hypertension (HTN) (3 arms), sponsored by Hengrui. Primary endpoint: Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 2 months. Started Jul 2019; status: completed.
02
Drugs
SHR0532
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03971929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971929.